Top Page | English | 简体中文 | 繁體中文 | 한국어 | 日本語
Friday, 22 June 2018, 10:58 HKT/SGT
Share:
    

Source: Eisai
Eisai Selected for Membership in MSCI Japan Empowering Women Index (WIN)

TOKYO, June 22, 2018 - (JCN Newswire) - Eisai Co., Ltd. announced today that it has been selected for the first time for membership in the MSCI Japan Empowering Women Index (WIN), an index developed for environmental, social and governance (ESG) investment. This index is one of the indices adopted by the Government Pension Investment Fund (GPIF) for selecting investments based on ESG initiatives as an indicator of non-financial value.

The MSCI Japan Empowering Women Index (WIN) is developed by MSCI Inc., the industry leader in ESG research who offers various tools to support the investment decisions of major investors around the world. For the MSCI Japan Empowering Women Index, MSCI selects industry leading companies in terms of attracting, retaining and promoting women, as well as advancing gender diversity. Selection is based on data regarding female employment disclosed according to the Act on Promotion of Women's Participation and Advancement in the Workplace as well as information publicly disclosed by companies such as company policy on gender diversity. In 2012, Eisai issued the Eisai Diversity Declaration, and implements various initiatives aimed at developing an organizational climate for utilizing diverse values as well as promoting the advancement of women.

Eisai has also been selected for inclusion in the FTSE Blossom Japan Index as well as the MSCI Japan ESG Select Leaders Index, which now means that Eisai has been selected for all three ESG indices for Japanese stocks adopted by the GPIF.

Eisai's corporate philosophy is to give first thought to patients and their families, and increase the benefits that health care provides as well as address diverse healthcare needs worldwide. By strengthening its ESG initiatives and increasing non-financial value, Eisai is striving to sustainably enhance corporate value based on this corporate philosophy.


Contact:
Media Inquiries: 
Public Relations Department,
Eisai Co., Ltd.
+81-(0)3-3817-5120


Topic: Press release summary
Source: Eisai

Sectors: BioTech
http://www.acnnewswire.com
From the Asia Corporate News Network


Copyright © 2025 ACN Newswire. All rights reserved. A division of Asia Corporate News Network.



Eisai
June 2, 2025 16:46 HKT/SGT
Eisai to Launch "Pariet S," the First Proton Pump Inhibitor RX-to-OTC in Japan
May 28, 2025 16:45 HKT/SGT
New Drug Approval for In-House Developed Anti-Insomnia Drug DAYVIGO (Lemborexant) in China
May 21, 2025 14:00 HKT/SGT
Eisai Demonstrates Commitment to Oncology Innovation at ASCO 2025
May 16, 2025 16:21 HKT/SGT
Eisai Satisfies All-Case Surveillance Requirement for Anticancer Agent Remitoro
Apr 30, 2025 13:17 HKT/SGT
Eisai Representative Corporate Officer and CEO Haruo Naito Awarded the Order of the Rising Sun, Gold and Silver Star
Apr 18, 2025 15:52 HKT/SGT
Leqembi (lecanemab) is the First Medicine that Slows Progression of Early Alzheimer's Disease to be Authorized in the European Union
Apr 1, 2025 12:15 HKT/SGT
Eisai to Divest Rights for Pariet in China to Peak Pharma
Mar 25, 2025 16:28 HKT/SGT
World's First Early Alzheimer's Disease Treatment Developed in Japan LEQEMBI Receives Prime Minister's Award at the 12th Technology Management and Innovation Awards
Mar 25, 2025 11:21 HKT/SGT
Eisai Selected as a Nadeshiko Brand 2025 as a Listed Company Excelling in Promotion of Women in the Workplace
Mar 10, 2025 19:24 HKT/SGT
Eisai Recognized as "2025 Kenko Investment for Health" for the First Time and Certified as "Outstanding Organization Of Kenko Investment for Health Program (White 500)" for the Sixth Time
More news >>
 News Alerts
Copyright © 2025 ACN Newswire - Asia Corporate News Network
Home | About us | Services | Partners | Events | Login | Contact us | Privacy Policy | Terms of Use | RSS
US: +1 214 890 4418 | China: +86 181 2376 3721 | Hong Kong: +852 8192 4922 | Singapore: +65 6549 7068 | Tokyo: +81 3 6859 8575

Connect With us: